Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

AXL targeting overcomes human lung cancer cell resistance to NK and CTL-mediated cytotoxicity.

Terry S, Abdou A, Engelsen AST, Buart S, Dessen P, Corgnac S, Collares D, Meurice G, Gausdal G, Baud V, Saintigny P, Lorens JB, Thiery JP, Mami-Chouaib F, Chouaib S.

Cancer Immunol Res. 2019 Sep 5. pii: canimm.0903.2019. doi: 10.1158/2326-6066.CIR-18-0903. [Epub ahead of print]

PMID:
31488404
2.

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1.

Leclerc M, Voilin E, Gros G, Corgnac S, de Montpréville V, Validire P, Bismuth G, Mami-Chouaib F.

Nat Commun. 2019 Jul 26;10(1):3345. doi: 10.1038/s41467-019-11280-z.

3.

Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.

Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F.

Nat Commun. 2018 Nov 30;9(1):5097. doi: 10.1038/s41467-018-07603-1.

4.

Resident memory T cells, critical components in tumor immunology.

Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C, Tihy I, Tartour E.

J Immunother Cancer. 2018 Sep 4;6(1):87. doi: 10.1186/s40425-018-0399-6. Review.

5.

The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin.

Corgnac S, Boutet M, Kfoury M, Naltet C, Mami-Chouaib F.

Front Immunol. 2018 Aug 15;9:1904. doi: 10.3389/fimmu.2018.01904. eCollection 2018. Review.

6.

Cancer Immunotherapy 2017 (Paris, France). Progress and challenges.

Chouaieb E, Terry S, Corgnac S, Engelsen AST.

Bull Cancer. 2018 May;105(5):537-541. doi: 10.1016/j.bulcan.2018.02.006. Epub 2018 Apr 12. No abstract available.

PMID:
29656785
7.

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.

Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F.

Front Immunol. 2018 Jan 22;9:14. doi: 10.3389/fimmu.2018.00014. eCollection 2018. Review.

8.

Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8+ Resident Memory T Cells in Tumors.

Gauthier L, Corgnac S, Boutet M, Gros G, Validire P, Bismuth G, Mami-Chouaib F.

Cancer Res. 2017 Dec 15;77(24):7072-7082. doi: 10.1158/0008-5472.CAN-17-1487. Epub 2017 Oct 11.

9.

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

Ghinnagow R, De Meester J, Cruz LJ, Aspord C, Corgnac S, Macho-Fernandez E, Soulard D, Fontaine J, Chaperot L, Charles J, Soncin F, Mami-Chouaib F, Plumas J, Faveeuw C, Trottein F.

Oncoimmunology. 2017 Aug 18;6(9):e1339855. doi: 10.1080/2162402X.2017.1339855. eCollection 2017.

10.

iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.

Corgnac S, Perret R, Zhang L, Mach JP, Romero P, Donda A.

J Immunother Cancer. 2014 Nov 18;2(1):39. doi: 10.1186/s40425-014-0039-8. eCollection 2014.

11.

Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function.

Zhang L, Tschumi BO, Corgnac S, Rüegg MA, Hall MN, Mach JP, Romero P, Donda A.

J Immunol. 2014 Aug 15;193(4):1759-65. doi: 10.4049/jimmunol.1400769. Epub 2014 Jul 11.

12.

Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.

Perret R, Sierro SR, Botelho NK, Corgnac S, Donda A, Romero P.

Cancer Res. 2013 Nov 15;73(22):6597-608. doi: 10.1158/0008-5472.CAN-13-0875. Epub 2013 Sep 18.

13.

CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.

Corgnac S, Perret R, Derré L, Zhang L, Stirnemann K, Zauderer M, Speiser DE, Mach JP, Romero P, Donda A.

Cancer Immunol Immunother. 2013 Apr;62(4):747-60. doi: 10.1007/s00262-012-1381-7. Epub 2012 Dec 15.

14.

SITC 26th annual meeting--summary.

Romano E, Nardelli-Haefliger D, Donda A, Corgnac S, Romero P.

J Transl Med. 2012 May 23;10:105. doi: 10.1186/1479-5876-10-105.

15.

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.

Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A, Navarro-Teulon I.

Breast Cancer Res. 2011 Feb 4;13(1):R17. doi: 10.1186/bcr2826.

16.

A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy.

Alvarez-Rueda N, Ladjemi MZ, Béhar G, Corgnac S, Pugnière M, Roquet F, Bascoul-Mollevi C, Baty D, Pèlegrin A, Navarro-Teulon I.

Vaccine. 2009 Jul 30;27(35):4826-33. doi: 10.1016/j.vaccine.2009.05.067. Epub 2009 Jun 11.

PMID:
19523913

Supplemental Content

Loading ...
Support Center